SCHEMBL4493681

SCHEMBL4493681

CN(C)CCCN(c1ccc(N/C(=C2\C(=O)Nc3cc(Cl)ccc32)c2cccc(CC(=O)O)c2)cc1)S(C)(=O)=O

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 2/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
SIRT2 Q8IXJ6 3/20 0.34
PDGFRB P09619 1/20 0.34
KIT P10721 1/20 0.34
FGFR1 P11362 1/20 0.34
KDR P35968 1/20 0.34
FLT3 P36888 1/20 0.34
PLK3 Q9H4B4 1/20 0.34
LMNA P02545 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HTT P42858 1/20 0.33
NR1H4 Q96RI1 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
MAPT P10636 3/20 0.33
GAA P10253 1/20 0.33
KDM4E B2RXH2 1/20 0.33
NPSR1 Q6W5P4 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4493686 1.00 PLK1 (0.36) PLK1MEN1KMT2ASIRT2PDGFRB
SCHEMBL4498605 0.96 KMT2A (0.35) PLK1MEN1KMT2ASIRT2PDGFRB
SCHEMBL4498601 0.96 KMT2A (0.35) PLK1MEN1KMT2ASIRT2PDGFRB
SCHEMBL227110 0.93 PLK1 (0.40) PLK1MEN1KMT2ASIRT2PDGFRB
SCHEMBL227109 0.93 PLK1 (0.40) PLK1MEN1KMT2ASIRT2PDGFRB
SCHEMBL4497689 0.92 CPT1A (0.36) PLK1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL4494487 0.92 CPT1A (0.36) PLK1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL4493418 0.91 KMT2A (0.36) MEN1KMT2ASIRT2KDRFLT3
SCHEMBL4493421 0.91 KMT2A (0.36) MEN1KMT2ASIRT2KDRFLT3
SCHEMBL4491940 0.90 GAA (0.36) PLK1MEN1KMT2ASIRT2PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed
EP-1527046-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-05-04 EP disclosed
WO-2004009546-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR PLK1 86/4885MEN1 1288/4885KMT2A 3530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.